Wanbury Limited

NSE WANBURY.NS

Wanbury Limited Receivables for the year ending March 31, 2024: USD 10.72 M

Wanbury Limited Receivables is USD 10.72 M for the year ending March 31, 2024, a 27.77% change year over year. Receivables are the amounts owed to the company by customers for goods sold or services rendered.

Wanbury Limited Receivables for the year ending March 31, 2023 was USD 8.39 M, a 1.48% change year over year.
Wanbury Limited Receivables for the year ending March 31, 2022 was USD 8.27 M, a 75.70% change year over year.
Wanbury Limited Receivables for the year ending March 31, 2021 was USD 4.71 M, a -30.16% change year over year.
Wanbury Limited Receivables for the year ending March 31, 2020 was USD 6.74 M, a 5.47% change year over year.

Key data

Date	Receivables	Inventory	Goodwill	Total Assets

NSE: WANBURY.NS

Wanbury Limited

CEO	Mr. Pradeep Patni
IPO Date	Jan. 29, 2007
Location	India
Headquarters	BSEL Tech Park, B-Wing
Employees	1,491
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cleaning Supplies Cosmetics Drugstores & Retail Pharmacies Personal Care Pet Food Plastics

Description

Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India. The company offers formulations for gynecology, orthopedics, heamatinics, anti-diabetic, nutraceuticals, gastro intestinal, stroke surgery, antibiotics, cough and cold solutions, anti-inflammatory, analgesics, and general practitioner purposes approximately under 70 brands. It also provides API products for anti-diabetic, anti-analgesic, anti-depressant, anti-histaminic, anti-inflammatory, anti-arthritis, anti-thrombotic, anti-epileptic, and anti-hypertensive therapeutic areas. Wanbury Limited also exports its products. The company was formerly known as Pearl Organics Limited and changed its name to Wanbury Limited in 2004. The company was incorporated in 1988 and is headquartered in Navi Mumbai, India.

Key trends

Past 5 years